This section hosts publications (updates, reports and guidelines) by the NHP and its network partners and affiliates.
Helpful reference document regarding the NHP MDT process and data flow, for regular and new referring clinicians.
The TCD QA Standards working group have published the 3rd Edition of Standards and Guidance in February 2026.
Learn more about the NHP Cellular Therapy Operational Group (CTG)
The guidance provides good practice advice for medical examiners on recognising the impact of SCD in various contexts including deaths and coroner referrals.
First iteration of the mortality reporting pathway for haemoglobinopathies.
The NHP activity report for 2023/2024 (published 21 November 2024) gives an overview of its core and partner-related activities.
Following the stepping down of Professor Baba Inusa, Dr Kate Gardner has been appointed the new NHP Chair.
Pfizer Shares Patient Advice Regarding Immediate Withdrawal of Voxelotor (Oxybryta®)
Following the unforeseen Pfizer withdrawal of Voxelotor (Oxbryta®) Medication for Sickle Cell Disease on 25th September 2024, the NHP provided a letter assist affected Sickle Cell Disorder patients.
NHS England sends a letter to centres regarding the 25.09.2024 withdrawal of Pfizer's Oxbryta (Voxelotor) drug for Sickle Cell Disorder.
University College London have produced a Standard Operating Procedure (SOP) for the assessment and work up of exagamglogene autotemcel (Casgevy™) for transfusion-dependent beta-thalassaemia
Home
About
The MDT
Science & innovation
News & features
Events
Contact
The National Haemoglobinopathy Panel
Guy's Hospital
(4th Floor, Southwark Wing)
Great Maze Pond
London, SE1 9RT
